摘要
骨髓源性内皮祖细胞(EPC)可在人胚胎时期以及出生后促进血管新生。EPC在生理和病理的情况下被招募到目的部位,分化为血管内皮细胞,修复损伤组织。在血管新生、内皮再生的组织工程和基因治疗方面,尤其在心血管疾病如心肌梗死、动脉粥样硬化等缺血性疾病治疗和减少冠心病植入支架再狭窄等方面具有重要意义。本文就EPC的概况及其在缺血性疾病中的应用做一综述。
Emerging evidence suggests that bone marrow-derived endothelial progenitor cell （EPC） contribute to tissue vascularization during both embryonic and postnatal physiological processes. Circulating EPC localize to sites of neovascularization and differentiate into endothelial cells in situ. Recent preclinical and pioneering clinical studies have shown that introduction of EPC can restore tissue vascularization in myocardial infarct, ischemic events of atherosclerosis and coronary stent restenosis. In this review, we discussed EPC general feature and its preliminary research in ischemic diseases.
出处
《世界临床药物》
CAS
2009年第5期292-296,共5页
World Clinical Drug
关键词
内皮祖细胞
缺血性疾病
进展
endothelial progenitor cell
ischemic disease
progress
